A Patient Report is available through our online portal: portal.guardanthealth.com. To set up an account, contact Client Services: 855.698.8887.
Guardant Health Laboratory: Martina Lefterova, MD PhD | CLIA ID: 05D2070300 | CAP #: 8765297
About the Test

Guardant Reveal™ is a minimal residual disease and recurrence monitoring test for the detection of cancer-derived circulating tumor DNA (ctDNA) in patients with CRC following definitive treatment. The Guardant Reveal™ test was developed and its performance characteristics were determined by Guardant Health, Inc. This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. This test may be used for clinical purposes and should not be regarded as investigational or for research only. Guardant Health’s clinical reference laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.

Testing performed at: Guardant Health
Laboratory Director: Martina Lefterova, MD PhD | CLIA ID: 05D2070300 | CAP #: 8765297 | 505 Penobscot Drive, Redwood City, CA, 94063, USA